Contribution of sex hormones to gender differences in schizophrenia: A review

Asian Journal of Psychiatry

Volumn 18, Issue , 2015, Pages 2-14

  da Silva, Tricia L ^a,b   Ravindran, Arun V ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Dehydroepiandrosterone and its sulfate; Estrogen and progesterone; Gender differences; Schizophrenia; Testosterone

Indexed keywords

ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE; PROGESTERONE; PROGESTERONE DERIVATIVE; RALOXIFENE; SEX HORMONE; TESTOSTERONE;

ACNE; COGNITION; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; HIRSUTISM; HUMAN; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SYMPTOM; FEMALE; MALE; METABOLISM; PHYSIOLOGY; PROTECTION; PSYCHOLOGICAL RATING SCALE; SYNAPTIC TRANSMISSION;

ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; NEUROPROTECTION; PROTECTIVE FACTORS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEX FACTORS; SYNAPTIC TRANSMISSION;

EID: 84955339175     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2015.07.016     Document Type: Review

References (136)

1. Abbs B., Liang L., Makris N., Tsuang M., Seidman L.J., Goldstein J.M. Covariance modeling of MRI brain volumes in memory circuitry in schizophrenia: sex differences are critical. Neuroimage 2011, 56(4):1865-1874.
2. Akhondzadeh S., Nejatisafa A.A., Amini H., Mohammadi M.R., Larijani B., Kashani L., Raisi F., Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(6):1007-1012.
3. Akhondzadeh S., Rezaei F., Larijani B., Nejatisafa A.A., Kashani L., Abbasi S.H. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr. Res. 2006, 84(2-3):405-410.
4. Arevalo M.A., Santos-Galindo M., Lagunas N., Azcoitia I., Garcia-Segura L.M. Selective estrogen receptor modulators as brain therapeutic agents. J. Mol. Endocrinol. 2011, 46(1):R1-R9.
5. Baudry M., Bi X., Aguirre C. Progesterone-estrogen interactions in synaptic plasticity and neuroprotection. Neuroscience 2013, 239:280-294.
6. Baumeister H., Härter M. Prevalence of mental disorders based on general population surveys. Soc. Psychiatry Psychiatr. Epidemiol. 2007, 42(7):537-546.
7. Begemann M.J.H., Dekker C.F., van Lunenburg M., Sommer I.E. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr. Res. 2012, 141(2-3):179-184.
8. Bergemann N., Mundt C., Parzer P., Pakrasi M., Eckstein-Mannsperger U., Haisch S., Salbach B., Klinga K., Runnenbaum B., Resch F. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr. Res. 2005, 74(2-3):125-134.
9. Bergemann N., Abu-Tair F., Strowitzki T. Estrogen in the treatment of late-onset schizophrenia. J. Clin. Psychopharmacol. 2007, 27(6):718-719.
10. Bergemann N., Parzer P., Runnebaum B., Resch F., Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 2007, 37(10):1427-1436.
11. Bergemann N., Parzer P., Jaggy S., Auler B., Mundt C., Maier-Braunleder S. Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr. Bull. 2008, 34(6):1172-1181.
12. Bergemann N., Parzer P., Kaiser D., Maier-Braunleder S., Mundt C., Klier C. Testosterone and gonadotropins but not estrogen associated with spatial ability in women suffering from schizophrenia: a double-blind, placebo-controlled trial. Psychoneuroendocrinology 2008, 33(4):507-516.
13. Białek M., Zaremba P., Borowicz K.K., Czuczwar S.J. Neuroprotective role of testosterone in the nervous system. Pol. J. Pharmacol. 2004, 56(5):509-518.
14. Bitzer J., Simon J.A. Current issues and available options in combined hormonal contraception. Contraception 2011, 84(4):342-356.
15. Bowie C.R., Depp C., McGrath J.A., Wolyniec P., Mausbach B.T., Thornquist M.H., Luke J., Patterson T.L., Harvey P.D., Pulver A.E. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 2010, 167(9):1116-1124.
16. Breier A., Buchanan R.W. The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients. Life Sci. 1992, 51(19):1527-1534.
17. Brinton R.D., Thompson R.F., Foy M.R., Baudry M., Wang J., Finch C.E., Morgan T.E., Pike C.J., Mack W.J., Stanczyk F.Z., Nilsen J. Progesterone receptors: form and function in the brain. Front. Neuroendocrinol. 2008, 29(2):313-339.
18. Cabeza R., Nyberg L. Imaging cognition II: an empirical review of 275 PET and fMRI studies. J. Cogn. Neurosci. 2000, 12(1):1-47.
19. Canuso C.M., Goldstein J.M., Wojcik J., Dawson R., Brandman D., Klibanski A., Schildkraut J.J., Green A.I. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002, 111(1):11-20.
20. Carter C.S., Barch D.M., Gur R., Gur R., Pinkham A., Ochsner K. CNTRICS final task selection: social cognitive and affective neuroscience-based measures. Schizophr. Bull. 2009, 35(1):153-162.
21. Castle D.J., Murray R.M. The neurodevelopmental basis of sex differences in schizophrenia. Psychol. Med. 1991, 21(3):565-575.
22. Ceskova E., Prikryl R., Kasparek T. Testosterone in first-episode schizophrenia. Neuro Endocrinol. Lett. 2007, 28(6):811-814.
23. Champagne J., Lakis N., Bourque J., Stip E., Lipp O., Mendrek A. Progesterone and cerebral function during emotion processing in men and women with schizophrenia. Schizophr. Res. Treat. 2012, 2012:917901. 10.1155/2012/917901.
24. Choi S.H., Kang S.B., Joe S.H. Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom. Med. 2001, 63(5):822-829.
25. Chua W.L., de Izquierdo S.A., Kulkarni J., Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst. Rev. 2005, 19(4):CD004719.
26. Cidis Meltzer C., Drevets W.C., Price J.C., Mathis C.A., Lopresti B., Greer P.J., Villemagne V.L., Holt D., Mason N.S., Houck P.R., Reynolds C.F., DeKosky S.T. Gender-specific aging effects on the serotonin 1A receptor. Brain Res. 2001, 895(1-2):9-17.
27. Cyr M., Calon F., Morissette M., Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J. Psychiatry Neurosci. 2002, 27(1):12-27.
28. Dhandapani A., Narayanaswamy J.C., Venkatasubramanian G. Adjuvant raloxifene treatment for negative symptoms of schizophrenia. Asian J. Psychiatry 2013, 6(3):254-255.
29. di Michele F., Caltagirone C., Bonaviri G., Romeo E., Spalletta G. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J. Psychiatr. Res. 2005, 39(3):267-273.
30. Diflorio A., Jones I. Is sex important? Gender differences in bipolar disorder. Int. Rev. Psychiatry 2010, 22(5):437-452.
31. Ebinger M., Sievers C., Ivan D., Schneider H.J., Stalla G.K. Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression?. J. Psychopharmacol. 2009, 23(7):841-853.
32. Elias A., Kumar A. Testosterone for schizophrenia. Cochrane Database Syst. Rev. 2012, 18(3):CD006197.
33. Elias A., Alias A.G., Abraham T., Gilza E.S., Sreekumari S., Mohandas E., Antony J.T., Elias M. Correlation between serum androgen levels and neuropsychological functions in schizophrenia. Eur. Psychiatry 2007, 22(1):S88.
34. Felthous A.R., Robinson D.B. Oral contraceptive medication in prevention of psychotic exacerbations associated with phases of the menstrual cycle. J. Prev. Psychiatry 1981, 1(1):5-14.
35. Gallagher P., Watson S., Smith M.S., Young A.H., Ferrier I.N. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr. Res. 2007, 90(1-3):258-265.
36. Garcia-Segura L.M., Azcoitia I., DonCarlos L.L. Neuroprotection by estradiol. Prog. Neurobiol. 2001, 63(1):29-60.
37. Ghafari E., Fararouie M., Shirazi H.G., Farhangfar A., Ghaderi F., Mohammadi A. Combination of estrogen and antispsychotics in the treatment of women with chronic schizophrenia. Clin. Schizophr. Relat. Psychoses 2013, 6(4):172-176.
38. Gogos A., Kwek P., van den Buuse M. The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology 2012, 219(1):213-224.
39. Goldstein J.M. Sex, hormones and affective arousal circuitry dysfunction in schizophrenia. Horm. Behav. 2006, 50(4):612-622.
40. Goldstein J.M., Cohen L.S., Horton N.J., Lee H., Andersen S., Tohen M., Crawford A., Tollefson G. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002, 110(1):27-37.
41. Goldstein J.M., Seidman L.J., O'Brien L.M., Horton N.J., Kennedy D.N., Makris N., Caviness V.S., Faraone S.V., Tsuang M.T. Impact of normal sexual dimorphisms on sex differences in structural brain abnormalities in schizophrenia assessed by magnetic resonance imaging. Arch. Gen. Psychiatry 2002, 59(2):154-164.
42. Good K.P., Kopala L.C., Martzke J.S., Fluker M., Seeman M.V., Parish B., Shapiro H., Whitehorne L. Hormone replacement therapy in postmenopausal women with schizophrenia: preliminary findings. Schizophr. Res. 1999, 12(3):131.
43. Goyal R.O., Sagar R., Ammini A.C., Khurana M.L., Alias A.G. Negative correlation between negative symptoms of schizophrenia and testosterone levels. Ann. N. Y. Acad. Sci. 2004, 1032:291-294.
44. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J. Clin. Psychiatry 2006, 67(10):e12.
45. Guest P.C., Schwarz E., Krishnamurthy D., Harris L.W., Leweke F.M., Rothermundt M., van Beveren N.J., Spain M., Barnes A., Steiner J., Rahmoune H., Bahn S. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011, 36(7):1092-1096.
46. Gur R.E., Turetsky B.I., Cowell P.E., Finkelman C., Maany V., Grossman R.I., Arnold S.E., Bilker W.B., Gur R.C. Temporolimbic volume reductions in schizophrenia. Arch. Gen. Psychiatry 2000, 57(8):769-775.
47. Gur R.E., Kohler C., Turetsky B.I., Siegel S.J., Kanes S.J., Bilker W.B., Brennan A.R., Gur R.C. A sexually dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia. Biol. Psychiatry 2004, 55(5):512-517.
48. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28(S2):17-54.
49. Halari R., Kumari V., Mehrotra R., Wheeler M., Hines M., Sharma T. The relationship of sex hormones and cortisol with cognitive functioning in schizophrenia. J. Psychopharmacol. 2004, 18(3):366-374.
50. Harris D.S., Wolkowitz O.M., Reus V.I. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J. Biol. Psychiatry 2001, 2(2):99-102.
51. Hendrick V., Altshuler L.L., Burt V.K. Course of psychiatric disorders across the menstrual cycle. Harv. Rev. Psychiatry 1996, 4(4):200-207.
52. Hoff A.L., Kremen W.S., Wieneke M.H., Lauriello J., Blankfeld H.M., Faustman W.O., Csernansky J.G., Nordahl T.E. Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am. J. Psychiatry 2001, 158(7):1134-1139.
53. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
54. Huber T.J., Rollnik J., Wilhelms J., von zur Mühlen A., Emrich H.M., Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001, 26(1):27-35.
55. Huber T.J., Borsutzky M., Schneider U., Emrich H.M. Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. Acta Psychiatr. Scand. 2004, 109(4):269-274.
56. Huber T.J., Tettenborn C., Leifke E., Emrich H.M. Sex hormones in psychotic men. Psychoneuroendocrinology 2005, 30(1):111-114.
57. Huerta-Ramos E., Iniesta R., Ochoa S., Cobo J., Miquel E., Roca M., Serrano-Blanco A., Teba F., Usall J. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur. Neuropsychopharmacol. 2014, 24(2):223-231.
58. Hughes Z.A., Liu F., Marquis K., Muniz L., Pangalos M.N., Ring R.H., Whiteside G.T., Brandon N.J. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr. Mol. Pharmacol. 2009, 2(3):215-236.
59. Irani F., Seligman S., Kamath V., Kohler C., Gur R.C. A meta-analysis of emotion perception and functional outcomes in schizophrenia. Schizophr. Res. 2012, 137(1-3):203-211.
60. Jimenez J., Lakis N., Mancini-Marie A., Mendrek A. The effect of testosterone on brain function associated with mental rotation in schizophrenia women. Int. Clin. Psychopharmacol. 2011, 26:e125.
61. Jiménez J.A., Mancini-Marïe A., Lakis N., Rinaldi M., Mendrek A. Disturbed sexual dimorphism of brain activation during mental rotation in schizophrenia. Schizophr. Res. 2010, 122(1-3):53-62.
62. Kaneda Y., Ohmori T. Relation between estradiol and negative symptoms in men with schizophrenia. J. Neuropsychiatry Clin. Neurosci. 2005, 17(2):239-242.
63. Keshavan M.S., Anderson S., Pettegrew J.W. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J. Psychiatr. Res. 1994, 28(3):239-265.
64. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62(6):617-627.
65. Kianimehr G., Fatehi F., Hashempoor S., Khodaei-Ardakani M.R., Rezaei F., Nazari A., Kashani L., Akhondzadeh S. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru 2014, 22:55.
66. Ko Y.H., Joe S.H., Cho W., Park J.H., Lee J.J., Jung I.K., Kim L., Kim S.H. Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 2006, 53(4):169-175.
67. Ko Y.H., Joe S.H., Cho W., Park J.H., Lee J.J., Jung I.K., Kim L., Kim S.H. Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia. Int. J. Psychiatry Clin. Pract. 2006, 10(2):97-104.
68. Ko Y.H., Jung S.W., Joe S.H., Lee C.H., Jung H.G., Jung I.K., Kim S.H., Lee M.S. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. Psychoneuroendocrinology 2007, 32(4):385-391.
69. Ko Y.H., Lew Y.M., Jung S.W., Joe S.H., Lee C.H., Jung H.G., Lee M.S. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2008, 28(4):375-383.
70. Krabbendam L., van Os J. Men with schizophrenia: a double disadvantage. Men's Health J. 2002, 1:114-117.
71. Kulkarni J., de Castella A., Taffe J. Clinical adjunctive estrogen trial in men with schizophrenia: a pilot study. Schizophr. Res. 1999, 36(1-3):286.
72. Kulkarni J., Gurvich C., Lee S.J., Gilbert H., Gavrilidis E., de Castella A., Berk M., Dodd S., Fitzgerald P.B., Davis S.R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010, 35(8):1142-1147.
73. Kulkarni J., de Castella A., Headey B., Marston N., Sinclair K., Lee S., Gurvich C., Fitzgerald P.B., Berger H. Estrogens and men with schizophrenia: is there a case for adjunctive therapy?. Schizophr. Res. 2011, 125(2-3):278-283.
74. Kulkarni J., Gavrilidis E., Wang W., Worsley R., Fitzgerald P.B., Gurvich C., Van Rheenen T., Berk M., Burger H. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol. Psychiatry 2015, 20(6):695-702.
75. Ladisich W. Influence of stress on regional brain serotonin metabolism after progesterone treatment and upon plasma progesterone in the rat. J. Neural Transm. 1975, 36(1):33-42.
76. Ladisich W. Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes. Psychoneuroendocrinology 1977, 2(3):257-266.
77. Lee D., Wang L., Dong P., Tran T., Copolov D., Lim A.T. Progesterone modulation of D5 receptor expression in hypothalamic ANP neurons, the role of estrogen. Mol. Psychiatry 2001, 6(1):112-117.
78. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. Suppl. 2000, 401:3-38.
79. Maninger N., Wolkowitz O.M., Reus V.I., Epel E.S., Mellon S.H. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front. Neuroendocrinol. 2009, 30(1):65-91.
80. Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L., Anderson G., Howard B.V., Thomson C.A., LaCroix A.Z., Wactawski-Wende J., Jackson R.D., Limacher M., Margolis K.L., Wassertheil-Smoller S., Beresford S.A., Cauley J.A., Eaton C.B., Gass M., Hsia J., Johnson K.C., Kooperberg C., Kuller L.H., Lewis C.E., Liu S., Martin L.W., Ockene J.K., O'Sullivan M.J., Powell L.H., Simon M.S., Van Horn L., Vitolins M.Z., Wallace R.B. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013, 310(13):1353-1368.
81. Markham J.A. Sex steroids and schizophrenia. Rev. Endocr. Metab. Disord. 2012, 13(3):187-207.
82. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008, 30:67-76.
83. Mendrek A., Stip E. Sexual dimorphism in schizophrenia: is there a need for gender-based protocols?. Exp. Rev. Neurother. 2011, 11(7):951-959.
84. Mendrek A., Fahim C., Mancini-Marie A., Boualem M., Stip E. An fMRI study of sex differences in emotion processing in schizophrenia. Schizophr. Bull. 2005, 31(2):427.
85. Mendrek A., Mancini-Marië A., Fahim C., Stip E. Sex differences in the cerebral function associated with processing of aversive stimuli by schizophrenia patients. Aust. N. Z. J. Psychiatry 2007, 41(2):136-141.
86. Mendrek A., Jimenez J., Mancini-Marie A. Functional neuroanatomy during mental rotation is influenced differently by testosterone in schizophrenia and in health. Schizophr. Res. 2008, 102(1-3 Suppl. 2):89.
87. Mendrek A., Jimenez J., Mancini-Marie A., Rinaldi M., Stip E., Lavoie M., Guillem F. Sex differences in cerebral activation during mental rotation in schizophrenia and in health. Schizophr. Res. 2008, 102(1-3 Suppl. 2):89-90.
88. Mendrek A., Mancini-Marïe A., Jiménez J., Rinaldi M., Germain M., Stip E., Lalonde P., Guillem F., Lavoie M. Sex differences in the processing of positive and negative affect in schizophrenia: an fMRI and ERP study. Schizophr. Bull. 2009, 35(S1):164.
89. Mendrek A., Lakis N., Jiménez J. Associations of sex steroid hormones with cerebral activations during mental rotation in men and women with schizophrenia. Psychoneuroendocrinology 2011, 36(9):1422-1426.
90. Mendrek A., Bourque J., Dubé A., Lakis A., Champagne J. Emotion processing in women with schizophrenia is menstrual cycle phase and affective valence dependent: an fMRI study. ISNR Psychiatry 2012, 656274.
91. Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 2012, 17(12):1206-1227.
92. Moore L., Kyaw M., Vercammen A., Lenroot R., Kulkarni J., Curtis J., O'Donnell M., Carr V.J., Shannon Weickert C., Weickert T.W. Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology 2013, 38(9):1717-1728.
93. Nachshoni T., Ebert T., Abramovitch Y., Assael-Amir M., Kotler M., Maayan R., Weizman A., Strous R.D. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr. Res. 2005, 79(2-3):251-256.
94. Ochoa S., Usall J., Cobo J., Labad X., Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr. Res. Treat. 2012, 2012:916198. 10.1155/2012/916198.
95. O'Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?. J. Clin. Psychopharmacol. 2005, 25(1):26-31.
96. Osterlund M.K., Hurd Y.L. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog. Neurobiol. 2001, 64(3):251-267.
97. Pohjalainen T., Rinne J.O., Nagren K., Syvalahti E., Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am. J. Psychiatry 1998, 155(6):768-773.
98. Rao L.R., Kolsch H. Effects of estrogen on brain development and neuroprotection-implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 2003, 28(S2):83-96.
99. Rettenbacher M.A., Mechtcheriakov S., Bergant A., Brugger A., Fleischhacker W.W. Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia. J. Clin. Psychiatry 2004, 65(2):275-277.
100. Riecher-Rossler A., Hafner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. Suppl. 2000, 407:58-62.
101. Ritsner M.S., Strous R.D. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. J. Psychiatr Res. 2010, 44(2):75-80.
102. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Biadsy H., Modai I., Weizman A. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 2005, 30(10):1913-1922.
103. Ritsner M., Gibel A., Ram E., Maayan R., Weizman A. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur. Neuropsychopharmacol. 2006, 16(2):137-146.
104. Ritsner M.S., Gibel A., Ratner Y., Tsinovoy G., Strous R.D. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychopharmacol. 2006, 26(5):495-499.
105. Ritsner M., Maayan R., Gibel A., Weizman A. Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. Eur. Neuropsychopharmacol. 2007, 17(5):358-365.
106. Ritsner M.S., Gibel A., Ratner Y., Weizman A. Dehydroepiandrosterone and pregnenolone alterations in schizophrenia. Neuroactive steroids in brain function, behavior and neuropsychiatric disorders 2008, 251-297. Springer, New York. M.S. Ritsner, A. Weizman (Eds.).
107. Ritsner M.S., Gibel A., Shleifer T., Boguslavsky I., Zayed A., Maayan R., Weizman A., Lerner V. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J. Clin. Psychiatry 2010, 71(10):1351-1362.
108. Rubin L.H., Carter C.S., Drogos L., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 2010, 124(1-3):13-21.
109. Salokangas R. Gender and the use of neuroleptics in schizophrenia. Schizophr. Res. 2004, 66(1):41-49.
110. Saugstad L.F. Age at puberty and mental illness. Towards a neurodevelopmental aetiology of Kraepelin's endogenous psychoses. Br. J. Psychiatry 1989, 155:536-544.
111. Schmidt S.J., Mueller D.R., Roder V. Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophr. Bull. 2011, 37(S2):S41-S54.
112. Seeman M.V., Cohen R. Puberty and schizophrenia. Curr. Opin. Psychiatry 1999, 12(S1):6-11.
113. Sharma E., Raveendranathan D., Shivakumar V., Jayaram N., Rao N.P., Venkatasubramanian G. Beneficial effects of add-on raloxifene in schizophrenia. A case report. Arch. Womens Ment. Health 2012, 15(2):147-148.
114. Shirayama Y., Hashimoto K., Suzuki Y., Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr. Res. 2002, 58(1):69-74.
115. Shivakumar V., Venkatasubramanian G. Successful use of adjuvant raloxifene treatment in clozapine-resistant schizophrenia. Ind. J. Psychiatry 2012, 54(4):394.
116. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. WHIMS Investigators, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289(20):2651-2662.
117. Silver H., Knoll G., Isakov V., Goodman C., Finkelstein Y. Blood DHEAS concentrations correlate with cognitive function in chronic schizophrenia patients. A pilot study. J. Psychiatr. Res. 2005, 39(6):569-575.
118. Singh M., Su C. Progesterone and neuroprotection. Horm. Behav. 2013, 63(2):284-290.
119. Sitruk-Ware R., Nath A. Metabolic effects of contraceptive steroids. Rev. Endocr. Metab. Disord. 2011, 12(2):63-75.
120. Smith S., Wheeler M.J., Murray R., O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J. Clin. Psychopharmacol. 2002, 22(2):109-114.
121. Snyder M.A., Gao W.J. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front. Cell. Neurosci. 2013, 7:31.
122. Strous R.D., Maayan R., Lapidus R., Goredetsky L., Zeldich E., Kotler M., Weizman A. Increased circulatory dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr. Res. 2004, 71(2-3):427-434.
123. Strous R.D., Maayan R., Kotler M., Weizman A. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clin. Neuropharmacol. 2005, 28(6):265-269.
124. Strous R.D., Stryjer R., Maayan R., Gal G., Viglin D., Katz E., Eisner D., Weizman A. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 2007, 32(2):96-105.
125. Szeszko P.R., Bilder R.M., Lencz T., Ashtari M., Goldman R.S., Reiter G., Wu H., Lieberman J.A. Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia. Schizophr. Res. 2000, 43(2-3):97-108.
126. Szeszko P.R., Strous R.D., Goldman R.S., Ashtari M., Knuth K.H., Lieberman J.A., Bilder R.M. Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. Am. J. Psychiatry 2002, 159(2):217-226.
127. Taherianfard M., Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Ind. J. Med. Sci. 2004, 58(1):3-9.
128. Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J. Clin. Psychiatry 2011, 72(S1):4-8.
129. Thompson K.N., Kulkarni J., Sergejew A.A. Extrapyramidal symptoms and oestrogen. Acta Psychiatr. Scand. 2000, 101(2):130-134.
130. Usall J., Huerta-Ramos E., Iniesta R., Cobo J., Araya S., Roca M., Serrano-Blanco A., Teba F., Ochoa S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 2011, 72(11):1552-1557.
131. van Rijn S., Aleman A., de Sonneville L., Sprong M., Ziermans T., Schothorst P., van Engeland H., Swaab H. Neuroendocrine markers of high risk for psychosis: salivary testosterone in adolescent boys with prodromal symptoms. Psychol. Med. 2011, 41(9):1815-1822.
132. Vercammen A., Skilleter A.J., Lenroot R., Catts S.V., Weickert C.S., Weickert T.W. Testosterone is inversely related to brain activity during emotional inhibition in schizophrenia. PLOS ONE 2013, 8(10):e77496. 10.1371/journal.pone.0077496.
133. Walder D.J., Seidman L.J., Makris N., Tsuang M.T., Kennedy D.N., Goldstein J.M. Neuroanatomic substrates of sex differences in language dysfunction in schizophrenia: a pilot study. Schizophr. Res. 2007, 90(1-3):295-301.
134. Wong J., Seeman M.V., Shapiro H. Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. Am. J. Geriatr. Psychiatry 2003, 11(6):697-698.
135. Yildirim O., Dogan O., Semiz M., Kilicli F. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives. Psychiatry Clin. Neurosci. 2011, 65(6):584-591.
136. Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance. Prog. Neurobiol. 2009, 89(2):134-152.